28.79 (-%)
As of Dec 02, 2024
Source:
Immunovant, Inc is a clinical-stage immunology company pursuing a broad anti-FcRn strategy based on the potential best-in-class profile of our lead asset, IMVT-1402, and informed by the breadth of the class, in which 23 indications have been publicly announced for study by multiple companies to date.
Country | United States |
Headquarters | new york, new york |
Phone Number | ( 917 ) 580-3099 |
Industry | manufacturing |
CEO | Peter Salzmann |
Website | www.immunovant.com |